Becton Dickinson and Company (BDX) , popularly known as BD, is scheduled to report first-quarter fiscal 2025 results on Feb. 6, before market open.See the Zacks Earnings Calendar to stay ahead of market-making news.In the last reported quarter, the company’s earnings per share (EPS) of $3.81 surpassed the Zacks Consensus Estimate by 1.1%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, delivering an earnings surprise of 6.5%, on average.Let’s check o ...

Analysts on Wall Street project that Becton Dickinson (BDX) will announce quarterly earnings of $2.98 per share in its forthcoming report, representing an increase of 11.2% year over year. Revenues are projected to reach $5.1 billion, increasing 8.4% from the same quarter last year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this ...

Becton Dickinson (BDX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Febr ...

Group 1 - The Board of Directors of BD has declared a quarterly dividend of $1.04 per common share, with an annual dividend rate of $4.16 per share [1] - BD has repurchased $750 million in stock to date in fiscal 2025 and has authorized the repurchase of up to 10 million additional shares [2] - The company is one of the largest global medical technology firms, focusing on improving medical discovery, diagnostics, and care delivery [3] Group 2 - BD employs over 70,000 individuals and is committed to enhancing the safety and efficiency of healthcare delivery [3] - The company collaborates with organizations worldwide to tackle significant global health challenges [3] - BD aims to improve outcomes, lower costs, increase efficiencies, and expand access to healthcare through innovative technology and solutions [3]

Becton, Dickinson and Company (BDX) , popularly known as BD, recently announced a collaboration with Biosero, a developer of laboratory automation solutions, to enable and facilitate robotic arm integration with BD flow cytometry instruments. This partnership aims to enhance the precision and efficiency of drug discovery and development processes, enabling researchers to streamline workflows and improve data accuracy.The integration leverages Biosero’s advanced automation software with BD’s flow cytometers, ...

FRANKLIN LAKES, N.J. and SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biosero, a developer of laboratory automation solutions to orchestrate scientific discoveries, today announced a framework collaboration agreement to enable and facilitate robotic arm integration with BD flow cytometry instruments to accelerate drug discovery and development. BD and Biosero, announced a framework collaboration agreement to enab ...

ROANOKE, Va. and FRANKLIN LAKES, N.J., Jan. 22, 2025 /PRNewswire/ -- Carilion Clinic, a not-for-profit health care organization serving more than 1 million people in Virginia, in partnership with BD, (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Carilion is the first health system in the state and the Southeastern U.S. to provide its patients needle-free blood draws using the BD® PIVO™ Pro Needle-free Blood Collection Device. This initiative i ...

FRANKLIN LAKES, N.J., Jan. 16, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Thursday, February 6, 2025 to discuss the Company's financial results for its first quarter of fiscal year 2025, which ended on December 31, 2024, and to provide an update on its operations and strategy. The audio webcast can be accessed at BD's investor relations website at www.bd.com/in ...

Core Viewpoint - BD (Becton, Dickinson and Company) is making significant investments in its U.S. manufacturing network to enhance the production capacity of critical medical devices, including syringes, needles, and IV catheters, in response to the ongoing needs of the healthcare system [1][2]. Investment and Capacity Expansion - In 2024, the company plans to invest over $10 million to expand manufacturing capacity, with new production lines for needles and syringes installed in Connecticut and Nebraska, one of which is already operational [3]. - The new production lines will increase BD's capacity for domestically manufactured safety-engineered injection devices by more than 40% and conventional syringes by over 50%, adding hundreds of millions of units annually [4]. Employment and Local Impact - BD has hired more than 215 full-time employees at its facilities in Nebraska and Connecticut to support the increased production [4]. - The company operates over 30 manufacturing and distribution facilities across the U.S., employing more than 10,000 people [7]. Future Plans - BD has plans for more than $30 million in investments in 2025 to expand manufacturing capacity for IV lines at its Utah plant, following a previous investment of over $2 million in 2024 that increased IV catheter output by more than 40 million units annually [5]. Commitment to U.S. Healthcare - The investments reflect BD's commitment to ensuring a resilient supply of essential healthcare devices and supporting the U.S. healthcare infrastructure [6]. - BD has a long history of manufacturing excellence in the U.S., with facilities in Nebraska, Connecticut, and Utah collectively having over 200 years of experience in producing critical medical devices [6].

BD Onclarity™ HPV Assay and New Guidelines - The BD Onclarity™ HPV Assay has been officially added to the ASCCP Enduring Risk-Based Management Guidelines due to its ability to individually identify more high-risk types of HPV [1][2] - The new guidelines represent a significant advancement in cervical cancer prevention and management, offering a more precise and effective approach to HPV screening, which improves treatment design and supports efforts to eliminate cervical cancer [2] - The BD Onclarity™ HPV Assay employs extended genotyping, allowing for a more detailed analysis of HPV types present in a person's body, which is crucial as HPV is the cause of virtually all cervical cancer [3] Extended Genotyping and Clinical Benefits - Traditional HPV tests typically identify no more than two high-risk HPV types individually, while the BD Onclarity™ HPV Assay can identify six of the 14 cancer-causing HPV types individually and group the remaining seven into three pooled results [4] - This extended genotyping allows for more precise risk assessment, persistence-tracking, and personalized treatment plans, aligning with new clinical recommendations [4] - Clinicians can more effectively manage high-risk cases and guide follow-up for low-risk patients by identifying specific HPV types and tracking them individually across patient visits [5] Self-Collection and Accessibility - The new ASCCP guidelines support the use of self-collection methods for cervical cancer screening, which is also offered with the BD Onclarity™ HPV Assay in healthcare settings [5] - Self-collection methods make it easier for women and people with a cervix to get screened, especially those facing barriers to traditional screening methods such as lack of time or discomfort with pelvic exams [5] - The recent FDA approval for self-collection in healthcare settings and the inclusion of extended genotyping in the ASCCP guidelines are expected to significantly improve access to potentially life-saving screening and the precision of screening results [6] Integration of New Technologies - The new guidelines integrate new technologies and approaches to improve cancer prevention for high-risk individuals and decrease unnecessary procedures in lower-risk individuals [7] - Extended genotyping results provide additional risk stratification beyond a pooled high-risk result, and repeated detection of the same HPV type, even a lower-risk strain, is associated with a much higher risk of cervical pre-cancer compared to single-time point detection [7] ASCCP Mobile Application Update - The ASCCP guidelines will soon be used to update the popular ASCCP mobile application, which is downloaded by over 150,000 clinicians in the US to help inform their decision-making and improve patient care [8] USPSTF Recommendations - Self-collection for HPV/cervical cancer screening is among the recommendations recently released for public comment by the US Preventive Services Task Force (USPSTF), which guides healthcare providers in the US on the effectiveness of specific preventive care services [9] About BD - BD is one of the largest global medical technology companies, advancing health by improving medical discovery, diagnostics, and the delivery of care [10] - The company develops innovative technology, services, and solutions to advance clinical therapy for patients and clinical processes for healthcare providers, with a presence in virtually every country and partnerships to address global health challenges [11]